— Know what they know.
Not Investment Advice

MGTA NASDAQ

Magenta Therapeutics, Inc.
1W: -6.0% 1M: -10.9% 3M: -0.1% 1Y: -65.5% 3Y: -90.0% 5Y: -94.7%
$0.70
Last traded 2023-09-11 — delisted
NASDAQ · Healthcare · Biotechnology · $42.4M mcap · 34M float · 0.580% daily turnover

Cash Flow Trends

Operating Cash Flow
-$129M -65.1% ▼
Capital Expenditures
$213K -102.9% ▼
5Y CAGR: -41.3%
Free Cash Flow
-$129M -65.1% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$317K +0.0% ▲
Net Change in Cash
$28M +125.8% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2024FY2025
— Operating Activities —
Net Income-$75M-$71M-$76M-$85M-$162M
Depreciation & Amort.$2M$2M$2M$412K$428K
Stock-Based Comp.$10M$10M$7M$13M$23M
Change in Working Capital-$1M-$2M-$3M$0$0
Other Non-Cash Items$180K$803K$3M-$7M$10M
Operating Cash Flow-$64M-$60M-$67M-$78M-$129M
— Investing Activities —
Capital Expenditures-$400K-$1M-$314K-$105K-$213K
Acquisitions (Net)$0$0$0$0$0
Investment Purchases-$96M-$45M-$69M-$414M-$435M
Investment Sales$86M$90M$60M$127M$312M
Other Investing$0$0$0$0$0
Investing Cash Flow-$11M$43M-$10M-$287M-$123M
— Financing Activities —
Net Debt Issuance$0$0$0$0$0
Stock Repurchased$104K$141K$115K$0$317K
Dividends Paid$0$0$0$0$0
Other Financing$68M$90M$3M$256M$280M
Financing Cash Flow$68M$90M$3M$256M$280M
Net Change in Cash-$7M$73M-$74M-$109M$28M
Cash End of Period$60M$133M$59M$23M$51M
Free Cash Flow-$64M-$61M-$67M-$78M-$129M

Free cash flow is operating cash flow minus capital spending. Finance-lease principal is not deducted, so it may read higher than a company figure that deducts it.

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms